N-(5-piperidin-1-yl-pentyl)-acetamide | 35070-03-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(5-piperidin-1-yl-pentyl)-acetamide
• 英文别名: N-(5-piperidino-pentyl)-acetamide；N-(5-Piperidino-pentyl)-acetamid；N-(5-piperidin-1-ylpentyl)acetamide
• CAS: 35070-03-2
• 化学式: C₁₂H₂₄N₂O
• mdl: MFCD16972690
• 分子量: 212.335
• InChiKey: FORQZCXHHBOQQD-UHFFFAOYSA-N

物化性质

• 沸点：
  374.6±25.0 °C(Predicted)
• 密度：
  0.949±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.916
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(5-piperidin-1-yl-pentyl)-acetamide 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 1-(5-ethylamino-pentyl)-piperidine
  参考文献：
  名称：

  Paul; Anand, Journal Of Scientific and Industrial Research, 1958, vol. 17B, p. 219,223

  摘要：

  DOI：
• 作为产物：
  描述：

  5-氯戊腈 在 吡啶 、 甲醇 、 氨 、 镍 、 苯 作用下， 生成 N-(5-piperidin-1-yl-pentyl)-acetamide
  参考文献：
  名称：

  Paul; Anand, Journal Of Scientific and Industrial Research, 1958, vol. 17B, p. 219,223

  摘要：

  DOI：

文献信息

• REAGENTS FOR QUANTITATIVE MASS SPECTROMETRY
  申请人：President and Fellows of Harvard College

  公开号：US20180209985A1

  公开（公告）日：2018-07-26

  In some embodiments, a mass spectrometry tag may comprise a linker region, a mass balance region, and a reporter region. The mass spectrometry tag may be configured to fragment in a mass spectrometer via an energy dependent process to produce multiple reporter molecules. For example, the reporter region of the tag may be configured to produce at least two reporter molecules via fragmentation. In some embodiments, one or more regions of the tag may comprise at least one heavy isotope. In some such embodiments, the ability to fragment into multiple reporter molecules as well as the placement and/or number of heavy isotope(s) allows the mass spectrometry tag to be distinguished from other similar mass spectrometry tags. In some such embodiments, the ability to distinguish between tags having the same or substantially similar total mass to charge ratio and reporter region mass may allow the system to have a greater multiplexing capacity than conventional systems.

  在某些实施例中，质谱标签可能包括一个连接区、一个质量平衡区和一个报告区。质谱标签可能被配置为在质谱仪中通过一个能量依赖的过程进行碎裂，以产生多个报告分子。例如，标签的报告区可能被配置为通过碎裂产生至少两个报告分子。在某些实施例中，标签的一个或多个区域可能包含至少一个重同位素。在某些这样的实施例中，能够碎裂成多个报告分子以及重同位素的位置和/或数量允许将质谱标签与其他类似的质谱标签区分开来。在某些这样的实施例中，能够区分具有相同或基本相似总质荷比和报告区质量的标签，可能使系统具有比传统系统更大的多重复用能力。
• Reagents for quantitative mass spectrometry
  申请人：President and Fellows of Harvard College

  公开号：US11169155B2

  公开（公告）日：2021-11-09

  In some embodiments, a mass spectrometry tag may comprise a linker region, a mass balance region, and a reporter region. The mass spectrometry tag may be configured to fragment in a mass spectrometer via an energy dependent process to produce multiple reporter molecules. For example, the reporter region of the tag may be configured to produce at least two reporter molecules via fragmentation. In some embodiments, one or more regions of the tag may comprise at least one heavy isotope. In some such embodiments, the ability to fragment into multiple reporter molecules as well as the placement and/or number of heavy isotope(s) allows the mass spectrometry tag to be distinguished from other similar mass spectrometry tags. In some such embodiments, the ability to distinguish between tags having the same or substantially similar total mass to charge ratio and reporter region mass may allow the system to have a greater multiplexing capacity than conventional systems.

  在某些实施方案中，质谱标签可包括连接区、质量平衡区和报告区。质谱标签可配置为通过能量相关过程在质谱仪中碎裂，以产生多个报告分子。例如，标签的报告区可配置为通过碎裂产生至少两个报告分子。在某些实施方案中，标签的一个或多个区域可包含至少一种重同位素。在一些这样的实施方案中，碎裂成多个报告分子的能力以及重同位素的位置和/或数量可使质谱标签与其它类似的质谱标签区分开来。在某些此类实施方案中，对具有相同或基本相似的总质量电荷比和报告区质量的标签进行区分的能力可使系统具有比传统系统更大的复用能力。
• 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS
  申请人：Amgen Inc.

  公开号：EP1817294A1

  公开（公告）日：2007-08-15
• US7488752B2
  申请人：——

  公开号：US7488752B2

  公开（公告）日：2009-02-10
• [EN] 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS<br/>[FR] 1,2,3,4-TETRAHYDROPYRAZIN-2-YLACETAMIDES ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DE BRADYKININE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：AMGEN INC

  公开号：WO2006019975A1

  公开（公告）日：2006-02-23

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds of formula (I) and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.